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Vascular inflammation, especially at the level of endothelial cells, has been shown to play a pivotal role in the
inception, progression, and clinical complications of atherosclerosis. The common denominators for the activation
of inflammatory genes appear to be a small subset of transcription factors—among which include nuclear factor-κB,
activator protein-1 (AP-1), andGATA—that function as the central hub of vascular inflammation. Strategies directed
to inhibit both the secondarymediators and the primary triggers (atherosclerosis risk factors) appear viable to inhibit
atherosclerosis. However, attempts have now been made to address the central hub of vascular inflammation. “Old”
drugs, such as dipyridamole, can also now be revisited for properties related to inhibition of vascular inflammation,
probably by acting on the common hub of inflammation.
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Introduction
Our knowledge on the pathophysiology of myocar-
dial infarction and of atherosclerotic vascular dis-
ease in general has gradually accrued over the past
two centuries but has received an important accel-
eration in the past 20 years. While myocardial in-
farction, since its first descriptions, has been linked
to coronary artery disease, the instabilization of
an otherwise smoldering disease—leading to acute
coronary syndromes—has been only the product of
knowledge of recent years. Today, “inflammation,”
in its broader sense, can comprehensively account
for the pathogenesis of vascular disease, including
its late clinical manifestations. Here, we will briefly
review recent knowledge in this area and highlight
how even “old fashioned” drugsmay need amodern
revisitation for properties previously unsuspected,
ultimately yielding potential new tools to combat
the disease of the past and the present century.
On the origin of myocardial infarction and
arterial instabilization
About 40 years ago, knowledge on the origin and
pathophysiology of atherosclerosis mostly revolved
on the entryof cholesterol esters intovascular intima
and on the correlation of such accumulation with
hemodynamic stress. Several studies had already
indeed correlated high levels of blood cholesterol
with atherosclerotic vascular disease. Other studies
had correlated the specific location of atheroscle-
rotic plaques in bifurcation and branching points
with the shear stress caused by the turbulence
of blood flow, considered responsible for the in-
creased endothelial permeability.1–3 The transport
of cholesterol in a free form through endothe-
lial cells and its deposition in intimal phagocytes
was being recognized, and gradually the role of
low-density lipoprotein (LDL) cholesterol gradu-
ally emerged as the principal trigger of atheroscle-
rosis.4–6 The body of knowledge acquired in those
years offered a reasonable interpretation on the
origin and progression of atherosclerosis in re-
lation to the well-appreciated risk factors for is-
chemic heart disease. But those years were also
witnessing a dispute, now resolved and forgotten
by most, on the pathogenesis of myocardial in-
farction on an atherosclerotic substrate: important
schools of thought, on both sides of the Atlantic
Ocean, considered the progressive severe stenosis of
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atherosclerotic arteries as the final trigger for acute
events.7,8
Many at that time believed that thrombosis was
secondary to blood stasis following the infarction,9
therefore a consequence and not a cause. Much of
this knowledge was based on pathological sections
of coronary arteries in autopsy material, where—
retrospectively interpreted—the variable time lag
between the onset of symptoms and death could ac-
count for the entire spectrum of possible findings,
supporting both the causality and the noncausality
hypotheses. If one study has to be quoted as a di-
vider between the time of quarreling and the time of
data consolidation indicating thrombosis as the fi-
nal trigger of plaque instabilization, this is the study
by De Wood et al., which showed the greater inci-
dence of total or subtotal coronary occlusion as an
inverse function of time elapsed between symptom
onset and the coronary angiographyused todemon-
strate the occlusion, with the retrieval of thrombotic
material through a Fogarty catheter when such in-
tervention was performed early in time.10 Davies
and coworkers, in 1985, illustrated the concept of
plaque fissuring as a common cause of the acute
manifestations of ischemic syndromes.11 Closing
the causality loop were, a few years later, the clinical
trials demonstrating the possibility of dramatically
reducing postmyocardial infarction mortality with
antithrombotic treatments.12–25 The focus at that
point could shift upstream, to understand the pre-
cipitating causes of arterial thrombosis.
The inflammatory theory of atherosclerosis
Atherosclerotic lesions begin as fatty streaks, areas
of intimal thickening due to the accumulation of
“foam cells” (essentially lipid-laden macrophages),
extracellular matrix, and lymphocytes.26–30 Mature
plaques, instead, consist of a thickened intima con-
taining a lipid-rich core (atheros, gruel), surrounded
by extracellular matrix. The lipid-rich core con-
tains abundant tissue factor, capable of activating
the extrinsic pathway of coagulation.31,32 The pres-
ence of a collagen-rich cap and of smooth muscle
cells around the core prevent the contact of blood
with the thrombogenic component.33 Smoothmus-
cle cells, stimulated by the presence of transform-
ing growth factor-" (TGF-"), fibroblast growth
factor-2, (FGF2), and platelet-derived growth fac-
tor (PDGF) produced by cells participating in the
inflammatory atherosclerotic process, indeed mi-
grate from the media towards the intima, secreting
several types of collagen and extracellular matrix
(types I and II collagen, elastin, proteoglycans, fi-
bronectin), contributing to the resistance to rupture
of the fibrous cap and preventing thrombosis,34–36
and switching from purely contractile cells into se-
creting and proliferating cells.37 Matrix digestion
instead occurs because of the production of spe-
cific proteinases, named matrix metalloproteinases
(MMPs), mostly by activated macrophages arrived
in the intimaas transformationof circulatingmono-
cytes and their local replication.
Many suchcellular aspects of atherosclerosis, such
as the passage of monocytes from peripheral blood
to tissues and macrophage activation, can be gener-
ically defined as “inflammatory.”32,38–40 Inflamma-
tion indeed, in its widest acception, can be defined
as the passage of cellular elements from the blood to
tissues in response to an injury on the vascular wall
or of surrounding tissues.41 Acute inflammation
(with the prevailing involvement of neutrophils),
cell-mediated immune responses (with a prevailing
involvement of lymphocytes), and atherosclerosis
(with the primary involvement of monocytes) are
three forms of “inflammatory” reactions, all char-
acterized by phenomena of passage of cells from the
blood to the tissues. Inflammatory aspects are also
the secretion ofmatrix and the collagenolytic degra-
dation of the matrix by enzymes, mostly deriving
frommacrophages. Inflammation is therefore at the
basis of all pathogenetic aspects of atherosclerosis,
from lesion inception (the adhesion and migration
of monocytes),41,42 to their growth (accumulation
of cells andmatrix),43 up to their clinical emergence
(plaque fissuring).44
Many molecular aspects of vascular inflamma-
tion present in atherosclerosis are also common to
acute inflammation and immune phenomena. All
these have at their basis a condition of endothelial
dysfunction (endothelial “activation”) with the ex-
pression by the endothelium of an adhesive phe-
notype towards various leukocyte subtypes from
peripheral blood.41 The very same localization of
atherosclerosis at particular sites of the vascular
tree can be explained by such phenomena. In-
deed, the preferential localization of atheroscle-
rosis in branching sites, where shear stresses are
low or oscillating, and produce temporal fluctua-
tions in the tangential friction exerted on endothe-
lial cells,45–47 can be explained by the activation
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of specific receptors responsive to such forces (shear
stress response sensors) and the ensuing nuclear
events involving shear stress response elements
(SSRE). These produce a cytoskeletal rearrange-
ments of endothelial cells, the surface expression
of endothelial adhesion molecules (intercellular ad-
hesion molecule (ICAM)-1, vascular cell adhesion
molecule (VCAM)-1, etc.), and a reduction in the
endothelial production of nitric oxide (NO) which,
in contrast to the other molecules quoted above,
increases in production when the shear stress is
laminar.48–50
The specificity of atherosclerosis versus other
forms of inflammation is essentially exerted at
the endothelial level, where the early selective ex-
pression of adhesion molecules for monocytes al-
lows these specific cells—and not neutrophils and
lymphocytes—to adhere preferentially to the ar-
terial endothelium, contrary to what occurs in
other forms of inflammation. The immunoglobulin
VCAM-1 is, in this context, very relevant in so far,
through the interaction with the integrin very late
activation antigen-4 (VLA4), expressed on mono-
cytes and some lymphocyte classes.51,52 VCAM-1-
VLA4 binding determines the selective recruitment
of this particular type of leukocytes. The expres-
sion of VCAM-1 by the endothelium is favored,
besides by a high laminar shear stress and turbu-
lent flow, by virtually all cardiovascular risk factors.
As examples, stimuli to its expression are modified
or oxidized LDL, advanced glycation endproducts
found abundantly in diabetes and uremia, primary
inflammatory cytokines such as interleukin (IL)-1
and tumor necrosis factor (TNF)-#, as well as bacte-
rial lipopolysaccharide (LPS).53,54 These substances
are therefore considered the soluble mediators of
vascular atherosclerotic disease, which conjure with
biomechanical factors in determining the extent and
localization of atherosclerosis.
As a confirmation of the relationship of in-
flammatory phenomena with atherosclerosis, one
may also remark the associations of atherosclerosis
with classically “inflammatory” diseases. Rheuma-
toid arthritis, as an example, is associatedwith ahigh
incidence of coronary heart disease. Both diseases
show similarities in the activation of T-lymphocytes
and mast cells, as well as in the production of TNF-
#, IL-6, and adhesion molecules. The production
of these and other cytokines by the synovial tissue
in subjects with rheumatoid arthritis has similari-
ties with the proatherogenic phenomena occurring
in subjects with vascular disease, such as conditions
of insulin resistance, dyslipidemias, endothelial ac-
tivation, and a prothrombotic phenotype. Patients
with rheumatoid arthritis feature high levels of C-
reactive protein (CRP), a marker of inflammation
associated with increased cardiovascular risk.55
The endothelium reacts to the proatherogenic ac-
tivation with the production of counter-regulatory
factors such as prostacyclin (PGI2), NO, heparin-
like complex polysaccharides able to activate an-
tithrombin, type 1 plasminogen activator (PAI-1),
protein S, thrombomodulin, and the secretion of
ILs with antiproliferative and anti-inflammatory
properties. In subjects with multiple risk factors for
atherosclerosis, a simultaneous reduction in the en-
dothelial production of such athero- and thrombo-
protective mechanisms occurs.
The changes in the normal homeostatic balance
between athero-protective and proatherogenic fac-
tors is generally explained by the activation, under
the pressure of atherogenic risk factors, of a com-
mon proinflammatory mechanism, which in turns
orchestrates the “pleiotropic” appearance of the en-
dothelial proatherogenic phenotype. Such common
mechanism may mostly be the transcription fac-
tor nuclear factor-!B (NF-!B) and a few other
transcription factors. These represent the “central
hub” of inflammation, a single intracellular system
on which proinflammatory/proatherogenic stimuli
converge determining its activation; and fromwhich
the various aspects of the pleiotropic endothelial
proinflammatory phenotypes branch out (Fig. 1).
Because of the multiplicity of the activation path-
ways (whereby the lack of one single activating stim-
ulus may be compensated by the higher level of ac-
tivation of other factors: the “redundancy” of the
system), it is difficult to imagine that limiting the
actions of one single risk factor may eradicate vas-
cular disease, but it is logical to conceive that it can
only serve to limit the problem. As a matter of fact,
this intuitive approach to the choice of therapeutic
targets in vascular disease has yielded appreciable
results as the main current therapeutic strategies
in vascular disease. One important consequence of
this reasoning is also however that the central hub of
inflammation (NF-!B, with the possible accessory
contribution of other transcription factors, such as
AP-1, GATA, egr-1), may be a reasonable target in
vascular inflammation.56
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Figure 1. Canonical and noncanonical pathways of activation of the transcription factor nuclear factor (NF)-!B. The NF-!B
systemcomprises a series of heterodymericmolecules (monomers includingRel-A/p65, p50, p52, Rel-B, c-Rel) normally sequestered
in the cytoplasm and bound to an inhibitor (I-!B). Under the influence of primary activating triggers (upper left inset), among
which include inflammatory cytokines, modified LDL, etc., the increased generation of reactive oxygen species leads to the binding
of I-!B with ubiquitin and the proteolytic degradation of I-!B. The heterodymers, made free from the inhibitor, can then migrate
into the nucleus, where they bind specific recognition (consensus) sequences in the promoter region of a variety of genes of
endothelial activation, with the final result of increased transcription of the respective genes (right lower inset). The partial overlap
in properties of the primary triggers (“redundancy,” e.g., the nearly identical pattern of endothelial activation evoked by IL-1
and TNF), results in a similar cellular activation by different stimuli. The fact that multiple genes, e.g., E-selectin, VCAM-1, and
ICAM-1, are expressed even when a single cytokine activates the system epitomizes the “pleiotropy” of the system, another property
of inflammatory cytokines. Reproduced, with changes, fromDeCaterina, R., A. Zampolli, G. Lazzerini & P. Libby. 2007. Endothelial
activation and the initiation of atherosclerosis. In Endothelial Dysfunctions in Vascular Disease. De Caterina, R. & P. Libby, Eds.:
26–35. Blackwell-Futura. New York, with permission by the publisher.
New biomarkers
This new knowledge on the central role of inflam-
mation in atherogenesis has indeed yielded an entire
new series of potential plasma biomarkers, different
from those commonly used previously (e.g., based
on the lipid profile), which largely overlap in report-
ingonpathogeneticmechanisms in vascular disease.
Potential biomarkershere includeVCAM-1,TNF-#,
IL-1, IL-18,MMPs, CD40L, adiponectin, PAI-1, fib-
rinogen, and several others.40 The ideal biomarker
should be easilymeasured, haveminimumcircadian
variations, and have a long half-life. CRP closely
matches such a description.57 Conversely, as an ex-
ample, PAI-1 has a half-life of about 6 h and features
important circadian variations.
CRP is predictive of cardiovascular events (my-
ocardial infarction, stroke, and sudden cardiac
death) in addition to measurements of LDL choles-
terol.58 For this reason, its measurement has been
proposed in addition to the list of classical risk fac-
tors basedon the Framinghamalgorithm.59 Subjects
with CRP < 1 mg/L are at low risk, whereas sub-
jects with levels >3 mg/L are at high risk. Risk of
ischemic heart disease and stroke in the latter sit-
uation indeed is increased by a factor of 1.3 and
1.6, respectively).60 Conversely, the evidence that
CRP may also be a mediator of vascular disease,
and therefore itself a potential therapeutic target,
appears much weaker, especially on the basis of re-
centMendelian randomization studies.60 Other new
potential biomarkers stemming out of our recent
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knowledge on vascular inflammation include CD40
ligand,61 adiponectin (as an inverse correlate),62 IL-
18,63 and some MMPs, potentially reporting on the
risk of plaque rupture,64 as well as TF, marking a
prothrombotic phenotype.65
New therapeutic approaches
A hypothesis remains a hypothesis, no matter how
attractive it is, until one can fully demonstrate its va-
lidity. The demonstration of the causality relation-
ship for the inflammatory hypothesis of atheroscle-
rosis requires the testing with adequate therapies.
We have several therapies available with an impact
on vascular atherosclerosis, but only few of them
are practicable on a large scale in prevention strate-
gies. These may largely be classified in three main
groups:
1. therapies acting on primary atherogenic trig-
gers,
2. therapies acting on the final effectors, and
3. therapies acting on the central common path-
way of vascular inflammation.
We will briefly discuss these and highlight where
novelties in this area may appear.
Therapies acting on primary atherogenic
triggers
To combat inflammation linked to atherosclerosis,
a first logical approach, followed for decades, has
been to limit the classical risk factors of vascular dis-
eases, with interventions on diet, physical activity,
the cessation on smoking, or the effects on specific
risk factors. Changes in lifestyles are unfortunately a
constant source of frustration. The latest EuroAspire
survey, which has produced a snapshot of practices
of secondary prevention in eight European coun-
tries in 2005, comparing it to previous surveys of
the same kind carried over in 1996 and 1998,66 has
shown how far we are from reaching the declared
objectives. We are much better in prescribing drugs,
mainly antihypertensive drugs and statins, than to
inducepeople to stop smoking, reduce caloric intake
or adopt healthy lifestyles. In any case, we are doing
something good for atherosclerosis when we limit
risk factors such as LDL cholesterol (with statins) or
hypertension (with antihypertensive drugs).
In doing all this, we also reduce vascular inflam-
mation. Statins are a particularly interesting class of
drugs in this respect. Beyond reducing LDL choles-
terol, statins also reduce markers of vascular in-
flammation, including IL-6, TNF, and CRP.67,68 If a
cholesterol-lowering therapy is anti-inflammatory,
it should reduce CRP. This is exactly what happens:
CRP is reduced by 15–50% with statins,57,69–72 in
what appears to be a class effect. If a reduced CRP
really is a measure of the probability of cardiovascu-
lar complications, cardiovascular risk should paral-
lel such a reduction. This is exactly what happens.
A recent study has indeed reported that in patients
with an acute coronary syndrome receiving statin
therapy, subjects with CRP < 2 mg/dL had a re-
duced risk of reinfarction or vascular death com-
pared with subjects with higher values (2.8 vs. 3.9
events per 100 persons-year; P< 0.006).58 This ben-
efit appears someway independent from reduction
in LDL cholesterol. Therefore, the clinical benefit
of statins seems to parallel anti-inflammatory ef-
fects. In any case, however, LDL reduction is itself
an anti-inflammatory therapy, and this activity ap-
pears central to the beneficial effect of statins.
A similar reasoning can be done for drugs in-
hibiting the renin–angiotensin system, angiotensin-
converting enzyme (ACE) inhibitors, and an-
giotensin receptor blockers, commonly used
throughout the spectrum of vascular disease.73,74
Therapies acting on the final effectors
Classical anti-inflammatory therapies are by many
considered the essential ingredients of a therapeutic
cocktail destined todemonstrate causality of inflam-
mation in atherosclerosis. However, many classical
anti-inflammatory therapies have contraindications
in patients with vascular disease. Glucocorticoids,
for example, were experimented with in the 1970s
in the acute phase of a myocardial infarction, but
their development with this indication was quickly
halted owing to a higher incidence of heart rupture.
Traditional nonsteroidal anti-inflammatory drugs,
as well as more recently developed cyclooxygenase
(COX)-2 selective inhibitors (coxibs), have a theo-
retical contraindication in that they limit vascular
production of prostacyclin, which is mainly COX-
2-dependent, and may compete for the antithrom-
botic effects of aspirin. Anticytokine drugs, which
selectively hit oneof themanyfinal targets of inflam-
mation, have been tested serendipitously. A therapy
with etanercept, a derivative of a monoclonal an-
tibody against TNF-#, has been experimented in a
phase 3 study inheart failure (theRENEWALstudy),
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without appreciable results even limited to purely
ischemic endpoints.75 The MRC-ILA-HEART trial
plans to study 186 patients with non-ST elevation
myocardial infarction in the United Kingdom using
anakinra, and IL-1 receptor antagonist (IL-1Ra).
The study will evaluate efficacy and safety of the
drug on circulating levels of CRP, as a prelude to a
possible efficacy phase 3 study.76 Similar approaches
are the possible interferences with the production or
activity of leukotrienes, with action at the level of 5-
lipoxygenase or at leukotriene receptors. Although
conceptually interesting, such approaches interfere
with only some of themultiple mediators of inflam-
mation potentially involved.
The case of dipyridamole
The total suppression of NF-!B activity, when tried
in animal experiments, interferes with embryogene-
sis and with immune functions, and does not there-
fore appears as a viable option. On the contrary, first
in in vitro and then in vivo in animal experiments,
several drugs generically defined as “antioxidant”
have been tested. Such drugs interfere with the gen-
eration of some reactive oxygen species, which are
in turn activators of NF-!B. One such substances,
succinobucol, has been brought to phase 3 in non-
ST elevation acute coronary syndromes within the
ARISE study, with mostly disappointing results.77
One should however mention that the extent of in-
hibition of NF-!B with the in vivo administration
of this drug was not as well documented as in vitro.
Methotrexate, a drug commonly used in rheumatic
diseases and relatively safe at low doses, might be
an alternative worth testing, and this approach is
currently being pursued.
An alternative option in this respect is to revisit
old drugs for which some clinical efficacy has been
already documented, and try to exploit novel no-
tions about their mechanism of action. One such
drug is dipyridamole. Originally branded as an an-
tiplatelet agent, the drug has still an uncertain role
in coronary heart disease (due to lack of data from
well-performed clinical trials), but has evidence of
efficacy in the prevention of ischemic stroke.78 In
ourownhands (unpublisheddata), thedrug reduces
monocytoid cell and endothelial cell pro-MMP9
and MMP-9 after TNF#/phorbol myristate acetate
or high-glucose stimulations, thus potentially re-
ducing mechanisms of instabilization of atheroscle-
rotic plaques (for the effect onmonocytes, the main
secretors of collagenolytic enzymes in the plaque,
and for the effect on endothelial cells, where re-
duction on MMPs should lead to reduced plaque
angiogenesis). Such effects appear to occur through
inhibition of NF-!B activation. At the endothelial
level, notably, dipyridamole induces endothelial cell
COX-2 expression, alone or after TNF#/PMA stim-
ulation, therefore not potentially curtailing the pro-
duction of endothelial prostacyclin. These observa-
tions are intriguing, although their clinical relevance
remains to be demonstrated.
Conclusions
Inflammationplays a central role in vascular disease,
from plaque inception to plaque progression and
instabilization. The now demonstrated sequence of
events linking inflammation with vascular disease
differs substantially from the old idea of vascular
disease as a problem of lipid accumulation. Inflam-
matory markers such as CRP, derived from such
knowledge, merit careful consideration to be in-
cluded in our algorithms of risk evaluation. Knowl-
edge of the mechanisms of vascular inflammation
also holds the promise of unraveling new targets
for therapeutics. Such new therapies may include
the revisitation of the mechanism of action of old
drugs.
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